Big discounts likely as auction looms for Woodford assets

Why Woodford may be forced to sell private biotech assets at a hefty discount as auction nears

While Neil Woodford’s Woodford Investment Management is expected to go ahead with an auction of its private biotech holdings this month, three healthcare investors told BioCentury it isn’t a sure thing the fund will be able to sell the stakes, and if it does, it is unlikely the prices will be anywhere near

Read the full 530 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers